由于多重耐药微生物的新疗法不可能产生很大的投资回报，因此，政府有义不容辞的责任让这一领域的研究对私营公司更具吸引力，此外，为了阻止耐药性的发展，还必须确保新药不被滥用。
Because new treatments for multidrug-resistant microbes aren’t expected to generate much return on investment, it is incumbent upon governments to make research and development in this field more attractive to private companies, and, in order to stem the development of resistance, to ensure that new drugs are not overused.